Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Infectious Disease

Articles with lock require a GLG News subscription
Posted May 5, 2008
Ricin Vaccine Market Relies on Threat of Terror
Analysis of: DOR BioPharma Initiates Non-Human Primate Efficacy Studies of RiVaxTM, Its Vaccine Against Ricin Toxin | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine Columbia University College of Physicians and Surgeons
Ricin is an extraordinarily potent toxin that is fatal because of its ability to inhibit protein synthesis and rapidly cause multisystem failure.  Because ricin can be prepared from castro beans, it has the potential to be used in terrorist attacks.  The present vaccine has the potential to...
Posted May 5, 2008
Can biologic drugs tackle antibiotic resistance?
Analysis of: Can biologic drugs tackle antibiotic resistance? | www.pharmaceutical-business-review.com
Author: GLG Member Program Contributor
Immunomodulation especially with antibodies is difficult.  Proteins are not as easily given and distributed through the body as low molecular weight compounds.  I believe that the first drug to be effective will pave the way for many others
Posted April 14, 2008
FDA Clears Glaxo Diarrhea - Virus Vaccine
Analysis of: FDA Clears Glaxo Diarrhea - Virus Vaccine | www.nytimes.com
Author: GLG Member Program Contributor
The key to success of marketing Rotarix or similar Rotavirus vaccines is in the design of clinical trials and evaluation of criteria and results of past use of these vaccines in developing countries that have a high incidence of rotavirus diarrhea in infants.  Rotavirus vaccine use...
Posted April 14, 2008
Cubist Finds Its Antibiotic Cubicin Is Tainted
Analysis of: Cubist Finds Its Antibiotic Cubicin Is Tainted | online.wsj.com
Author: GLG Member Program Contributor
            ReadyMED® is a infusion device used primarily in outpatient settings for administering antiobiotics in the home.  ReadyMED® requires little patient or caregiver training and works by gravity.  No IV poles or pumps...
Eric Gruff Posted April 14, 2008
Cubist's Antibiotic Cubicin is Tainted: A Mess Not of Their Doing? Maybe, Maybe Not.
Analysis of: Cubist Finds Its Antibiotic Cubicin Is Tainted | online.wsj.com
Author: Eric Gruff, Principal E4 Consulting
The news that Cubist's Cubicin has been contaminated with 2-mercaptobenzothiazole (MBT) has caused great concern for patients. It appears that the MBT has leeched out of the Cardinal Health ReadyMED drug pumps that are used for delivering Cubicin. Regardless of who is at fault, everyone involved (Cubist,...
Posted April 7, 2008
FDA Clears Glaxo Diarrhea - Virus Vaccine
Analysis of: FDA Clears Glaxo Diarrhea - Virus Vaccine | www.nytimes.com
Author: GLG Member Program Contributor
-Glaxo's Rotarix vaccine was approved last week for prevention of rotavirus infection in infants -Merck's product, Rotateq, on the market for 2 years in the US, already has an established pipeline to essentially all pediatric primary care providers -There are small differences between the 2 vaccines,...
Posted April 4, 2008
Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment
Analysis of: Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment | pharmalive.com
Author: GLG Member Program Contributor
This article fails to explain how Lipsovir will prevent breakouts of new lesions.  They say that early use of the ointment in an episode will shorten the duration about 1 1/2 days but where is the evidence that it prevent new episodes?  Also there is a lot of viral resistance to acyclovir,...
Posted March 31, 2008
Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine Achieves Protective Levels
Analysis of: Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine Achieves Protective Levels | www.pipelinereview.com
Author: GLG Member Program Contributor
This drug in the form of a patch will solve one problem of vaccination for the Pandemic Flu; that is the two-step process. It also may have impact on the autistic concerns associated with immunizations that are administered containing small amounts of mercury.
Posted March 31, 2008
Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment
Analysis of: Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment | pharmalive.com
Author: GLG Member Program Contributor
The article published in the www.pharmalive.com is presenting a very useful information for preventing common illness, such as cold sores. The successful clinical outcome from phase III trial for Lipsovir is a progressive step for Medivir to develop preventative medicine. Particularly,  the combination...
Posted March 28, 2008
Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment
Analysis of: Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment | pharmalive.com
Author: GLG Member Program Contributor
Many patients wish to rid themselves of recurrent cold sores. If this cream really works, there will be a market for it.
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 Next11 to 20 of 210

GLG News: What Experts Think Is Important





Analytics